Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]

Consultation comments

A consultation on the suggested remit, draft scope and provisional stakeholder list of consultees and commentators for this appraisal was included in the scope consultation for the appraisal of treatments for non-small-cell lung cancer (pathway appraisals pilot, ID6234).

NICE’s response to comments on the draft scope and provisional stakeholder list can be found in the project documents section of the ID6234 web page. Please note that not all comments in that document are relevant for the appraisal of durvalumab as neoadjuvant then adjuvant treatment for resectable non-small-cell lung cancer.

Final scope

The final scope was reissued on 30 November 2023 with a slight change to the population.